Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin
暂无分享,去创建一个
[1] M. Gulliford,et al. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study , 2004, Diabetes/metabolism research and reviews.
[2] E. Cerasi,et al. Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? , 1996, Diabetologia.
[3] J. Leahy,et al. Is metformin cardioprotective? , 2003, Diabetes care.
[4] S. Majumdar,et al. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. , 2002, Diabetes care.
[5] A. Tenenbaum,et al. Oral antidiabetic treatment in patients with coronary disease: Time‐related increased mortality on combined glyburide/metformin therapy over a 7.7‐year follow‐up , 2001, Clinical cardiology.
[6] G. Lindberg,et al. Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study , 2000, Diabetologia.
[7] Teven,et al. MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .
[8] David M Nathan,et al. Some answers, more controversy, from UKPDS , 1998, The Lancet.
[9] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[10] R. Holman,et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.
[11] M. Laakso,et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. , 1998, The New England journal of medicine.
[12] D. Boyle,et al. The diabetes audit and research in Tayside Scotland (darts) study: electronic record linkage to create a diabetes register , 1997, BMJ.
[13] J. Evans,et al. The Tayside Medicines Monitoring Unit (MEMO) : a record-linkage system for pharmacovigilance , 1995 .
[14] V. Carstairs,et al. Deprivation and health in Scotland. , 1990, Health bulletin.
[15] Brämer Gr. International statistical classification of diseases and related health problems. Tenth revision. , 1988, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.
[16] H. Seltzer. A Summary of Criticisms of the Findings and Conclusions of the University Group Diabetes Program (UGDP) , 1972, Diabetes.
[17] B. Schneider. MANUAL of the international statistical classification of diseases, injuries, and causes of death. Addendum 1. Supplementary interpretations and instructions for coding causes of death. , 1953, Bulletin of the World Health Organization. Supplement.